( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Easter Godwin Nwokah* and Smart Enoch Amala


Extended-spectrum β-lactamase-producing (ESBLs) organisms are a major challenge today in hospital and community-acquired infections. These plasmid-mediated enzymes hydrolyze extended spectrum Cephalosporins like Ceftazidime, Cefotaxime which are used in the treatment of urinary tract infections (UTI) and rendering them ineffective. This study was undertaken to determine the prevalence of extended spectrum beta lactamase-producing uropathogens in a sub-urban setting. 250 mid-stream clean catch urine samples were collected randomly from consenting subjects at Nchia, Eleme, Rivers State. Samples were analysed microbiologically for significant bacteriuria. Significant asymptomatic bacteriuria was detected in 92 (36.8%) of the total study population of 250 subjects. Distribution of the isolates showed Escherichia coli as the highest occurring isolate (40.2%), followed by Klebsiella pneumoniae (26.1%). The least isolated is Pseudomonas spp (1.1%). Study also showed 26 (28.3%) of the isolates as ESBL producers with Escherichia coli and Klebsiella pneumoniae accounting for 57.7% and 26.9% respectively. Furthermore, based on species, 15 (40.5%) of 37 Escherichia coli and 7 (29.2%) of 24 Klebsiella pneumoniae were ESBL producers. On antibiotic susceptibility testing, isolates showed highest susceptibility to the Carbapenems- Meropenem (100%) and Imipenem (96.7%). All the ESBL isolates were susceptible to the carbapenems emphasizing their high therapeutic value. Susceptibility to Ciprofloxacin was 82.6% while the Cephalosporins- Ceftazidime, Cefotaxime and Ceftriaxone – showed 66.3%, 65.2% and 63.0% susceptibilities respectively. Highest level of resistant was observed in ampicillin (6.5%). Most of the ESBL producing isolates were multidrug resistant. Besides antimicrobial susceptibility testing, it has become very necessary, in our setting, to include routine screening for ESBL to guide therapy for UTI.

Keywords: Urinary tract infection, Antimicrobial Resistance, Extended spectrum ?-lactamases.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 July 2024 Issue has been Published, Kindly check it on


    JULY 2024 issue has been successfully launched on JULY 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia